Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
11.95
+0.51 (4.46%)
Jul 27, 2026, 4:00 PM EDT - Market closed
Phathom Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 180.9 | 129.97 | 297.26 | 381.39 | 155.39 | 183.26 |
Cash & Short-Term Investments | 180.9 | 129.97 | 297.26 | 381.39 | 155.39 | 183.26 |
Cash Growth | -14.79% | -56.28% | -22.06% | 145.45% | -15.21% | -36.26% |
Accounts Receivable | 80.72 | 78.13 | 38.8 | 1.64 | - | - |
Inventory | 6.51 | 5.52 | 3.21 | 1.21 | - | - |
Other Current Assets | 8.44 | 15.35 | 20.87 | 13.19 | 5.13 | 3.27 |
Total Current Assets | 276.57 | 228.97 | 360.13 | 397.43 | 160.51 | 186.53 |
Net Property, Plant & Equipment | 3.52 | 3.67 | 2.09 | 3.62 | 3.49 | 2.56 |
Other Long-Term Assets | 25.03 | 26.51 | 16.1 | 12.79 | 0.8 | 0.34 |
Total Assets | 305.12 | 259.15 | 378.32 | 413.84 | 164.81 | 189.43 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 6.37 | 4.98 | 10.51 | 12.6 | 10 | 5.15 |
Accrued Expenses | 84.99 | 91.66 | 54.94 | 18.34 | 15.53 | 13.28 |
Current Portion of Leases | 0.67 | 0.65 | 0.5 | 0.73 | 0.71 | 0.49 |
Other Current Liabilities | 33.02 | 34.75 | 19.78 | 7.11 | - | - |
Total Current Liabilities | 125.04 | 132.04 | 85.73 | 38.78 | 26.24 | 18.92 |
Long-Term Debt | 163.68 | 209.09 | 201.41 | 137.84 | 95.26 | 89.67 |
Long-Term Leases | 1.96 | 2.07 | - | 0.46 | 1.1 | 1.18 |
Other Long-Term Liabilities | 351.4 | 354.12 | 344.76 | 309.52 | 117.03 | 7.5 |
Total Long-Term Liabilities | 517.03 | 565.27 | 546.17 | 447.82 | 213.39 | 98.35 |
Total Liabilities | 642.08 | 697.32 | 631.9 | 486.6 | 239.62 | 117.28 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 1,178 | 1,046 | 1,009 | 855.92 | 652.28 | 601.52 |
Retained Earnings | -1,515 | -1,484 | -1,263 | -928.69 | -727.09 | -529.37 |
Shareholders' Equity | -336.96 | -438.17 | -253.58 | -72.76 | -74.81 | 72.16 |
Total Liabilities & Equity | 305.12 | 259.15 | 378.32 | 413.84 | 164.81 | 189.43 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 166.3 | 211.8 | 201.91 | 139.03 | 97.07 | 91.34 |
Net Cash (Debt) | 14.6 | -81.83 | 95.35 | 242.36 | 58.32 | 91.92 |
Net Cash Growth | 66.79% | - | -60.66% | 315.61% | -36.56% | -61.46% |
Net Cash Per Share | 0.19 | -1.12 | 1.51 | 4.72 | 1.49 | 2.48 |
Book Value | -336.96 | -438.17 | -253.58 | -72.76 | -74.81 | 72.16 |
Book Value Per Share | -4.47 | -6.01 | -4.01 | -1.42 | -1.91 | 1.95 |
Tangible Book Value | -336.96 | -438.17 | -253.58 | -72.76 | -74.81 | 72.16 |
Tangible Book Value Per Share | -4.47 | -6.01 | -4.01 | -1.42 | -1.91 | 1.95 |